Hinge Health, Inc. (HNGE) is a San Francisco–based digital health company that sells app-and-sensor-based care for musculoskeletal conditions — back, knee, shoulder and joint pain — to self-insured employers, health plans and pharmacy benefit managers, and has expanded into migraine and gastrointestinal care. Its stock climbed 4.85% on Monday, trading at $120.99 by late afternoon against Friday's close of $115.39, a gain of $5.60. The direction was unambiguously higher, and the advance stood out because it came without a corresponding company announcement, regulatory filing or research note. Market participants attributed the move to buying interest returning after Friday's sharp pullback rather than to any newly disclosed development.
No verified news or fundamental catalyst found during the session explains Monday's gain. There was no earnings release, guidance update, contract award, financing, regulatory decision or sell-side rating change tied to the move. The company's last material disclosure was its third-quarter report on Nov. 2, which delivered revenue of $235.0 million — up 52% year over year — non-GAAP operating income of $77.2 million at a 33% margin, and a full-year revenue guidance raise to $879–$881 million, roughly 50% growth at the midpoint.
The most plausible technical explanation is a rebound from Friday's 4.63% decline, which followed disclosure that co-founder and director Gabriel Mecklenburg sold 200,000 Class A shares at an average price between $121.76 and $125.50 under a pre-arranged Rule 10b5-1 plan. That filing hit a stock already testing its highs, and Monday's action is consistent with dip-buying after a one-day flush. The pattern also fits a name that has gained roughly 148% year to date and has repeatedly produced daily swings above 5% — including five such sessions since late September alone. Friday's intraday low of $112.80 now marks the nearest reference point for traders defending the uptrend.
While nothing new was published Monday, the underlying bid still rests on a broadly supportive analyst reset in early November. Following the third-quarter beat, price targets were lifted across the Street into the $131–$145 range, with several firms arguing that enrollment yield and a nearly 30% larger client base support growth above market rates into 2027. The consensus target now sits well above the current share price, which has kept pullbacks shallow. That backdrop is real but two weeks old, and it does not by itself account for a single-session gain of this size.
Participation was not exceptional. With roughly an hour left in the regular session, volume was tracking below the 10-day average of about 1.95 million shares, suggesting the advance was driven by modest buying rather than a surge of institutional demand. The move was also divergent: most digital-health and healthcare-software peers traded lower on the day, leaving HNGE as a clear outlier within its own group.
Technically, the stock remains well above its 50-day moving average near $104 and has now recovered Friday's lost ground, but it has not cleared the Nov. 11 high of $126.40. Monday's range of roughly $115.39 to $122.00 held above the prior session's low, a constructive short-term signal after a higher-volume down day.
The scale runs from 0, meaning no meaningful news and a price move that is ordinary for the stock, to 100, meaning transformative news combined with an extreme, rare price move. Hinge Health earns 19 out of 100.
The news component is weak: no verified development surfaced on Monday, and the only substantive fundamental catalyst in the recent past is a third-quarter report that has already been digested. The price component is moderate but capped by the stock's own history. Monday's 4.85% gain was roughly 2.3 times the typical 2.13% absolute daily move over the past 74 sessions, yet moves of that magnitude or larger occurred six times in the last 60 sessions alone. A weak catalyst paired with a large-but-not-rare move produces a low score.
The next scheduled catalyst is fourth-quarter and full-year 2026 results, expected in early February 2027. Management has guided to fourth-quarter revenue of $249–$251 million, about 46% growth, and a 33% non-GAAP operating margin. Investors will focus on the 2027 selling season, expected roughly flat average selling price, and whether enrollment yield can keep climbing from the raised 4.6% assumption. The integrated GI program, targeted for summer 2027, and the Migraine rollout in the first quarter of 2027 are the key product milestones. Risks include a stretched valuation near 12 times sales, continued insider sales, sensitivity to large-employer benefit budgets, and the tendency of high-multiple digital-health names to de-rate quickly if growth decelerates.
Tickeron's Trending AI Robots page curates the automated strategies performing strongest under present market conditions from a library of hundreds of AI trading bots covering thousands of tickers. Bots differ by strategy, timeframe, performance metrics and traded symbols, so the featured list changes as conditions shift. Reviewing it is a practical way to see how systematic models are positioning right now — visit the page to compare the current leaders.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HNGE saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 13, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 12 instances where the indicator turned negative. In 11 of the 12 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The 10-day RSI Indicator for HNGE moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 8 similar instances where the indicator moved out of overbought territory. In 4 of the 8 cases, the stock moved lower in the following days. This puts the odds of a move lower at 50%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 12 of 15 cases where HNGE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HNGE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
HNGE broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Following a +6.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where HNGE advanced for three days, in 82 of 96 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 71 of 80 cases where HNGE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 25 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. HNGE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: HNGE's P/B Ratio (27.129) is slightly higher than the industry average of (4.523). P/E Ratio (14.015) is within average values for comparable stocks, (12.601). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (10.504) is also within normal values, averaging (6.105).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HNGE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ServicestotheHealthIndustry